DIA 2013 49th Annual Meeting to Address Hot Topics Surrounding Patient Therapies

Share Article

Sessions to highlight patient voices, alzheimer’s, big data.

The DIA 2013 49th Annual Meeting, to be held June 23–27 at the Boston Convention & Exhibition Center, will feature 22 tracks and more than 250 educational offerings, including sessions addressing urgent issues surrounding patient advocacy, big data and Alzheimer’s. These sessions, along with a large number of panels, forums and networking opportunities, aim to foster collaboration and drive conversation between patients and key industry and regulation professionals to advance the development and regulation of safe and effective medical products.

Sessions include:

Big Data: Impact on Innovation, June 25, 10:15 a.m. - Susan Dentzer, editor-in-chief of the leading peer-reviewed medical journal Health Affairs, will chair this discussion about how data are being used to support safety and efficiency, about how data affect the payer landscape, and to share best practices. Dentzer will be joined by keynote speaker Michael Rosenblatt, chief medical officer of Merck & Co., along with an esteemed panel of experts representing the pharmaceutical industry, regulatory affairs, clinical research and patient perspectives.

Advancing Alzheimer’s Innovation, June 26 - A variety of sessions will focus on advancing care in Alzheimer’s disease, bringing together representatives from the patient advocacy and industry communities.

  • A Call to Action, 10:15 a.m. - Meryl Comer, president of the Geoffrey Beene Foundation, will chair this discussion about the global impact of Alzheimer’s and the progress toward earlier detection, along with key steps being taken to address the growing epidemic.
  • Patient Advocacy, Caregiver Support and Health Care System Impact, 1:45 p.m. - Leaders from Sanofi and the Alliance for Aging Research will discuss how to foster collaboration to bridge the gap between industry and regulators, and enhance clinical trials and data collection.
  • Clinical Development Successes and Challenges, 4:00 p.m. - Top executives from Eisai Inc. and Merck & Co., and leading researchers from Massachusetts Alzheimer’s Disease Research Center, will discuss the challenges encountered in early and late clinical development, lessons learned from past trials and recommendations in trial design.

Patient Advocacy Panel, June 24, 10 a.m. - A panel of current fellows and alumni from the DIA Patient Advocate Fellowship Program will share inspiring stories of advancing patient care through their organizations. Patients and advocates will discuss how organizations can take vital steps to improve development of treatment, such as setting up registries to collect patient data, educating patients on diseases, working hand in hand with clinicians and researchers, identifying and boosting attendance for clinical trials and navigating the pharmaceutical industry and regulation to advance the development of treatment for diseases, especially in cases in which no treatment yet exists.

For more information, visit http://www.diahome.org.

About DIA
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related medical products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well-being worldwide. Headquarters are in Horsham, Pa., with offices in Basel, Switzerland; Tokyo; Mumbai, India; and Beijing.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website